EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter randomized phase III study evaluating epirubicin/cyclophosphamide versus epirubicin/docetaxel for first line treatment of metastatic breast cancer An interim analysis of safety and efficacy



Multicenter randomized phase III study evaluating epirubicin/cyclophosphamide versus epirubicin/docetaxel for first line treatment of metastatic breast cancer An interim analysis of safety and efficacy



Breast Cancer Research & Treatment 76(Supplement 1): S90, December




(PDF 0-2 workdays service: $29.90)

Accession: 035349909

Download citation: RISBibTeXText



Related references

Multicenter randomized phase III study evaluating epirubicin-cyclophosphamide versus epirubicin-docetaxel for first-line treatment of metastatic breast cancer Good tolerability and efficacy of epirubicin-docetaxel in heavily pretreated patients with high tumor load. Breast Cancer Research & Treatment 82(Supplement 1): S128, 2003

Randomized multicenter phase III study of epirubicin/paclitaxel versus epirubicin/cyclophosphamide in first-line treatment of metastatic breast cancer A study of the AGO breast cancer study group. Seminars in Oncology 26(6 Suppl 18): 8, 1999

Gemcitabine, epirubicin and paclitaxel vs 5-fluorouracil, epirubicin and cyclophosphamide as first-line treatment in metastatic breast cancer Interim toxicity analysis of a randomised, multicenter phase III trial of the Central European Cooperative Oncology Group. European Journal of Cancer 37(Supplement 6): S194, October, 2001

Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): An interim safety analysis. Journal of Clinical Oncology 23(16_suppl): 719-719, 2016

Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial. Annals of Oncology 21(7): 1430-1435, 2010

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. Journal of Clinical Oncology 23(7): 1401-1408, 2005

A randomized multicenter phase III trial comparing epirubicin and paclitaxel with epirubicin and cyclophosphamide as first line chemotherapy in patients with metastatic breast cancer. Breast Cancer Research & Treatment 57(1): 84, 1999

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology 18(1): 52-57, 2006

6 cycles of Epirubicin /Taxotere versus 6 cycles of 5FU/Epirubicin /Cyclophosphamide as first line metastatic breast cancer treatment Preliminary results of a randomized phase II trial. Breast Cancer Research & Treatment 64(1): 79, November, 2000

Epirubicin/docetaxel versus 5FU/epirubicin/cyclophosphamide combinations as first line chemotherapy in patients with metastatic breast cancer. Breast Cancer Research & Treatment 69(3): 215, October, 2001

Phase II multicenter sequential study of docetaxel (T) and epirubicin (E) followed by docetaxel (T) and capecitabine (X) as first-line treatment of advanced or metastatic breast cancer (MBC). Journal of Clinical Oncology 23(16_suppl): 707-707, 2016

Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study. Tumori 92(1): 6-12, 2006

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Research and Treatment 139(3): 779-787, 2014

Efficacy and safety results from a randomized, phase II trial of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide vs 5-FU + epirubicin plus cyclophosphamide in operable breast cancer. 2007